Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study.

Vincenzo SpagnuoloMarta VoarinoMarco TonelliLaura GalliAndrea PoliElena BruzzesiSara RaccaNicola ClementiChiara OltoliniMoreno TresoldiPatrizia Rovere QueriniLorenzo DagnaAlberto ZangrilloFabio CiceriMassimo ClementiAntonella Castagnanull null

Published in: Drug design, development and therapy (2022)

Time to VC was similar in cases and controls. However, there was a benefit associated with using RDV in regard to time to VC in younger patients and in those with a P/F ratio ≤200 mmHg at hospital admission.

Keyphrases

sars cov
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
healthcare
emergency department
prognostic factors
peritoneal dialysis
patient reported outcomes
respiratory syndrome coronavirus
patient reported